Literature DB >> 14744755

T-bet regulates metastasis rate in a murine model of primary prostate cancer.

Stanford L Peng1, Michael J Townsend, Jonathan L Hecht, Ian A White, Laurie H Glimcher.   

Abstract

The local progression of primary tumors is extrinsically controlled by type 1 immune responses, particularly via the cytokine IFN-gamma, whose secretion is highly dependent on helper T cells. The T-box transcription factor T-bet (Tbx21) plays a critical role in the development of type 1 helper T cells and is essential for the production of IFN-gamma. Here, the T-bet pathway in the autochthonous transgenic adenocarcinoma mouse prostate model is demonstrated to have only a modest effect on the characteristics of primary prostate cancers but rather exerts a significant suppressor function in the development of metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14744755     DOI: 10.1158/0008-5472.can-03-3401

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Association between gastric cancer and -1993 polymorphism of TBX21 gene.

Authors:  Le-Hui Zhang; Qin Li; Peng Li; Sheng-Tao Zhu; Jing Wang; Hong-Li Yang; Chang-Qing Xu; Xiu-Hua Guo
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

2.  Crystal structure of the DNA binding domain of the transcription factor T-bet suggests simultaneous recognition of distant genome sites.

Authors:  Ce Feng Liu; Gabriel S Brandt; Quyen Q Hoang; Natalia Naumova; Vanja Lazarevic; Eun Sook Hwang; Job Dekker; Laurie H Glimcher; Dagmar Ringe; Gregory A Petsko
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-10       Impact factor: 11.205

3.  The role of the Th1 transcription factor T-bet in a mouse model of immune-mediated bone-marrow failure.

Authors:  Yong Tang; Marie J Desierto; Jichun Chen; Neal S Young
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

4.  Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer.

Authors:  Mona Karlsson; Per Marits; Kjell Dahl; Tobias Dagöö; Sven Enerbäck; Magnus Thörn; Ola Winqvist
Journal:  Ann Surg Oncol       Date:  2010-01-30       Impact factor: 5.344

5.  T-bet plays a key role in NK-mediated control of melanoma metastatic disease.

Authors:  Miriam B F Werneck; Geanncarlo Lugo-Villarino; Eun Sook Hwang; Harvey Cantor; Laurie H Glimcher
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

6.  Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells.

Authors:  Wendy S Garrett; Shivesh Punit; Carey A Gallini; Monia Michaud; Dorothy Zhang; Kirsten S Sigrist; Graham M Lord; Jonathan N Glickman; Laurie H Glimcher
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

7.  Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia.

Authors:  C Wu; S Wang; F Wang; Q Chen; S Peng; Y Zhang; J Qian; J Jin; H Xu
Journal:  Clin Exp Immunol       Date:  2009-08-11       Impact factor: 4.330

8.  Gadd45b and Gadd45g are important for anti-tumor immune responses.

Authors:  Songguang Ju; Yibei Zhu; Lin Liu; Shao Dai; Changyou Li; Elizabeth Chen; Yukai He; Xueguang Zhang; Binfeng Lu
Journal:  Eur J Immunol       Date:  2009-11       Impact factor: 5.532

9.  Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes.

Authors:  Jeong-Hwan Yoon; Su Myung Jung; Seok Hee Park; Mitsuyasu Kato; Tadashi Yamashita; In-Kyu Lee; Katsuko Sudo; Susumu Nakae; Jin Soo Han; Ok-Hee Kim; Byung-Chul Oh; Takayuki Sumida; Masahiko Kuroda; Ji-Hyeon Ju; Kyeong Cheon Jung; Seong Hoe Park; Dae-Kee Kim; Mizuko Mamura
Journal:  EMBO Mol Med       Date:  2013-10-11       Impact factor: 12.137

10.  Prostate Cancer in a Male with Holt-Oram Syndrome: First Clinical Association of the TBX5 Mutation.

Authors:  Noel J Aherne; Guhan Rangaswamy; Pierre Thirion
Journal:  Case Rep Urol       Date:  2013-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.